Catalog Advanced Search
Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver DiseaseContains 8 Component(s) Recorded On: 11/09/2018
AASLD's Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver Disease presented at The Liver Meeting® 2018.
The hemodynamic changes in Fontan circulation (the palliative intervention in single ventricle physiology) confer risk of liver complications, particularly congestive hepatopathy. This program will include descriptions of the hepatopathy, the pathobiology of Fontan associated liver fibrosis, available diagnostic tools including imaging techniques and transplant-related medical decision making in the context of a failing Fontan.
Career Development WorkshopContains 9 Component(s) Recorded On: 11/09/2018
AASLD's Career Development Workshop presented at The Liver Meeting® 2018.
This workshop will look at various training pathways for a career in hepatology. It will also describe various career opportunities in research, practice, education and industry, providing an overview of the rewards and challenges for each of these, and identify sources for research funding for fellows and junior faculty members.
Oren K. Fix
Emily Rothbaum Perito
Kathleen E. Corey
Lawrence S. Friedman
Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.
Mark W. Russo
Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized MedicineContains 7 Component(s) Recorded On: 11/09/2018
AASLD's Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine presented at The Liver Meeting® 2018.
This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics. Finally, the role of genetics and epigenetics in the evaluation of the patient in the clinic will be addressed – with particular reference to diagnosis, prognosis and therapeutics.
Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ TransplantsContains 11 Component(s) Recorded On: 11/10/2018
AASLD's Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ Transplants presented at The Liver Meeting® 2018.
This program will review the current status of liver transplantation in the setting of combined organ transplants (i.e., liver/intestine/multi-visceral, liver/ kidney, liver/heart and liver/lung transplantation). Indications, pathophysiology, operative management, post-transplant care and outcomes will be discussed in the context of specific extra-hepatic organ dysfunction and combined organ transplantation. The session will also address the immunologic, ethical, financial and operational issues associated with multi-organ transplant as well as integration of these combined organ transplants in the overall liver allocation framework.
Richard Shane Mangus
Patrick S. Kamath
2018 Clinical Hepatology DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Clinical Hepatology Debrief presented at The Liver Meeting® 2018.
This session provides a summary of the clinical highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
K. Rajender Reddy
2018 Hepatitis DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Hepatitis Debrief presented at The Liver Meeting® 2018.
This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Jordan J. Feld
Leon Schiff State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Leon Schiff State-of-the-Art Lecture presented at The Liver Meeting® 2018.
This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.
Michael W. Fried (Moderator)
Arun J. Sanyal
2018 NAFLD DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's NAFLD Debrief presented at The Liver Meeting® 2018.
This session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Mary E. McCarthy Rinella
Hyman J. Zimmerman Hepatotoxicity State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/12/2018
AASLD's Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture presented at The Liver Meeting® 2018.
Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.
Raymond T. Chung (Moderator)
Naga P. Chalasani
2018 Advances for PractitionersContains 5 Component(s) Recorded On: 11/12/2018
AASLD's Advances for Practitioners presented at The Liver Meeting® 2018.
This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding screening issues for patients with cirrhosis will be reviewed.
Michael B. Fallon
Juan G. Abraldes
Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.
Nicolas M. Intagliata